534 related articles for article (PubMed ID: 32556942)
1. Severe COVID-19 and aging: are monocytes the key?
Pence BD
Geroscience; 2020 Aug; 42(4):1051-1061. PubMed ID: 32556942
[TBL] [Abstract][Full Text] [Related]
2. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
[TBL] [Abstract][Full Text] [Related]
3. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.
Merad M; Martin JC
Nat Rev Immunol; 2020 Jun; 20(6):355-362. PubMed ID: 32376901
[TBL] [Abstract][Full Text] [Related]
4. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
5. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
6. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".
Meftahi GH; Jangravi Z; Sahraei H; Bahari Z
Inflamm Res; 2020 Sep; 69(9):825-839. PubMed ID: 32529477
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2: a storm is raging.
Pedersen SF; Ho YC
J Clin Invest; 2020 May; 130(5):2202-2205. PubMed ID: 32217834
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
9. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.
Alunno A; Carubbi F; RodrÃguez-Carrio J
RMD Open; 2020 May; 6(1):. PubMed ID: 32423970
[TBL] [Abstract][Full Text] [Related]
10. Covid-19: Perspectives on Innate Immune Evasion.
Taefehshokr N; Taefehshokr S; Hemmat N; Heit B
Front Immunol; 2020; 11():580641. PubMed ID: 33101306
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
Schijns V; Lavelle EC
Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
[TBL] [Abstract][Full Text] [Related]
12. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.
Coperchini F; Chiovato L; Croce L; Magri F; Rotondi M
Cytokine Growth Factor Rev; 2020 Jun; 53():25-32. PubMed ID: 32446778
[TBL] [Abstract][Full Text] [Related]
13. Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?
Hazeldine J; Lord JM
Front Immunol; 2020; 11():573662. PubMed ID: 33123152
[TBL] [Abstract][Full Text] [Related]
14. Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.
Chen J; Kelley WJ; Goldstein DR
J Immunol; 2020 Jul; 205(2):313-320. PubMed ID: 32493812
[TBL] [Abstract][Full Text] [Related]
15. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
16. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
Front Immunol; 2020; 11():1022. PubMed ID: 32574260
[TBL] [Abstract][Full Text] [Related]
17. Cytokine storm induced by SARS-CoV-2.
Song P; Li W; Xie J; Hou Y; You C
Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
Busetto GM; Porreca A; Del Giudice F; Maggi M; D'Agostino D; Romagnoli D; Musi G; Lucarelli G; Palmer K; Colonna di Paliano A; Muto M; Hurle R; Terracciano D; de Cobelli O; Sciarra A; De Berardinis E; Ferro M
Urol Int; 2020; 104(7-8):510-522. PubMed ID: 32516772
[TBL] [Abstract][Full Text] [Related]
19. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies.
Dhama K; Patel SK; Pathak M; Yatoo MI; Tiwari R; Malik YS; Singh R; Sah R; Rabaan AA; Bonilla-Aldana DK; Rodriguez-Morales AJ
Travel Med Infect Dis; 2020; 37():101755. PubMed ID: 32479816
[TBL] [Abstract][Full Text] [Related]
20. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
Chang FY; Chen HC; Chen PJ; Ho MS; Hsieh SL; Lin JC; Liu FT; Sytwu HK
J Biomed Sci; 2020 Jun; 27(1):72. PubMed ID: 32498686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
